• Merck withdraws Keytruda indication for metastatic small cell lung cancer

    1 month ago - By Healio

    Merck voluntarily withdrew pembrolizumab's indication in the United States for treatment of certain patients with metastatic small cell lung cancer.
    The indication applied to use of pembrolizumab - an anti-PD-1 antibody - by patients whose disease progressed on or after platinum-based chemotherapy and at least one other prior line of therapy.
    The company made the decision in consultation with the FDA after a confirmatory phase 3 trial of pembrolizumab for this indication failed to meet one of its dual primary endpoints.
    The FDA granted accelerated approval to
    Read more ...